Data cast more doubt on Avastin's benefit in older NSCLC patients
This article was originally published in Scrip
Executive Summary
Roche/Genetech's Avastin (bevacizumab) may not prolong life in older patients with non-small cell lung cancer and should not be considered standard of care in this context, say researchers in a new study published in the Journal of the American Medical Association.